Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IX001 TCR-T in Advanced Pancreatic and Colorectal Cancer with KRAS Mutations
NCT06487377Phase 1Withdrawn
- Sponsor
- Shanghai Pudong Hospital
- Start
- Jul 2024
- Primary completion
- Mar 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IX001 TCR-T cells in pancreatic cancer (PC) and colorectal cancer (CRC), sponsored by Shanghai Pudong Hospital. Primary endpoints: Dose-limiting Toxicity at 4 weeks, Adverse Events at 96 weeks and 1 more. Planned start Jul 2024; status: withdrawn.
02
Drugs
IX001 TCR-T cells
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06487377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487377.